NGS Combined With RNAseq on Tumor Immune Escape in NSCLC

Shanghai Pulmonary Hospital, Shanghai, China

Status: Unknown

Conditions: Non-small Cell Lung Cancer

Treatments: Other: Time

Study type: Observational

Funder types: Other

Identifiers

NCT03764917

YS2018-003

Details and patient eligibility

About

Study on the tumor immune escape in advanced non-small cell lung cancer patients with EGFR and ALK mutant negative by NGS combined with RNAseq

Full description

Study on the tumor immune escape in advanced non-small cell lung cancer patients with EGFR and ALK mutant negative by NGS combined with RNAseq. Detecting non-small cell lung cancer patient NGS and RNAseq data before first-line chemotherapy, after two cycles chemotherapy and after disease progression.

Enrollment: 100 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Non-small cell lung cancer patient First-line chemotherapy with platinum-based chemotherapy

Exclusion criteria

EGFR mutant positive Alk mutant positive